RIPK1 and neoplasm: Together with in vitro experiments showing the same number of OVA-specific OT-I cells more efficiently kill OVA-expressing, SHARPIN-deficient versus WT B16F1 cells via a TNF-dependent mechanism (Figure 6D), our findings demonstrate that tumor cell destruction, analogous to transplant rejection, is dependent upon T cell–produced TNF that triggers target tissue RIPK1–dependent cell death.